These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23922886)

  • 1. Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).
    Zou Y; Howell GM; Humphrey LE; Wang J; Brattain MG
    PLoS One; 2013; 8(7):e69992. PubMed ID: 23922886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
    Camp ER; Yang A; Gray MJ; Fan F; Hamilton SR; Evans DB; Hooper AT; Pereira DS; Hicklin DJ; Ellis LM
    Cancer; 2007 Mar; 109(6):1030-9. PubMed ID: 17311308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
    O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
    Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome.
    Yu PT; Babicky M; Jaquish D; French R; Marayuma K; Mose E; Niessen S; Hoover H; Shields D; Cheresh D; Cravatt BF; Lowy AM
    Int J Cancer; 2012 Oct; 131(8):1744-54. PubMed ID: 22275185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells.
    Cho SB; Park YL; Song YA; Kim KY; Lee GH; Cho DH; Myung DS; Park KJ; Lee WS; Chung IJ; Choi SK; Kim KK; Joo YE
    Oncol Rep; 2011 Dec; 26(6):1581-6. PubMed ID: 21874262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration.
    Jaquish DV; Yu PT; Shields DJ; French RP; Maruyama KP; Niessen S; Hoover H; A Cheresh D; Cravatt B; Lowy AM
    Carcinogenesis; 2011 Aug; 32(8):1151-6. PubMed ID: 21565828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma.
    Kim SA; Lee KH; Lee DH; Lee JK; Lim SC; Joo YE; Chung IJ; Noh MG; Yoon TM
    Int J Oncol; 2019 Aug; 55(2):513-526. PubMed ID: 31268163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.
    Thangasamy A; Rogge J; Ammanamanchi S
    J Biol Chem; 2009 May; 284(21):14001-10. PubMed ID: 19307182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
    Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
    Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.
    Koh XY; Koh XH; Hwang LA; Ferrer FJ; Rahmat SAB; Lama D; Lane DP
    Oncogene; 2019 Nov; 38(48):7342-7356. PubMed ID: 31417186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.
    Thomas RM; Toney K; Fenoglio-Preiser C; Revelo-Penafiel MP; Hingorani SR; Tuveson DA; Waltz SE; Lowy AM
    Cancer Res; 2007 Jul; 67(13):6075-82. PubMed ID: 17616662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
    Vanderwerff BR; Church KJ; Kawas LH; Harding JW
    Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.
    Hu CY; Xu XM; Hong B; Wu ZG; Qian Y; Weng TH; Liu YZ; Tang TM; Wang MH; Yao HP
    Front Oncol; 2019; 9():1377. PubMed ID: 31867280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage stimulating protein preserves blood brain barrier integrity after intracerebral hemorrhage through recepteur d'origine nantais dependent GAB1/Src/β-catenin pathway activation in a mouse model.
    Lu T; Wang Z; Prativa S; Xu Y; Wang T; Zhang Y; Yu L; Xu N; Tang J; You W; Chen G; Zhang JH
    J Neurochem; 2019 Jan; 148(1):114-126. PubMed ID: 30380151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells.
    Chung CY; Park YL; Song YA; Myung E; Kim KY; Lee GH; Ki HS; Park KJ; Cho SB; Lee WS; Jung YD; Kim KK; Joo YE
    Dig Dis Sci; 2012 Feb; 57(2):371-80. PubMed ID: 21901254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.
    Wu Z; Zhang Z; Ge X; Lin Y; Dai C; Chang J; Liu X; Geng R; Wang C; Chen H; Sun M; Guo W; Li J
    Oncotarget; 2015 Dec; 6(38):40519-34. PubMed ID: 26528757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.
    Feres KJ; Ischenko I; Hayman MJ
    Oncogene; 2009 Jan; 28(2):279-88. PubMed ID: 18836480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma.
    Berning P; Hennemann C; Tulotta C; Schaefer C; Lechtape B; Hotfilder M; El Gourari Y; Jürgens H; Snaar-Jagalska E; Hempel G; Dirksen U; Potratz J
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer.
    Millar R; Kilbey A; Remak SJ; Severson TM; Dhayade S; Sandilands E; Foster K; Bryant DM; Blyth K; Coffelt SB
    Mol Oncol; 2020 Aug; 14(8):1868-1880. PubMed ID: 32484599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.